AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The comp...

ABBVIE INC. (ABBV) has a valuation score of 62/100 (moderate), profitability score of 58/100 (moderate), financial health score of 46/100 (weak), Piotroski F-Score of 8/9, Altman Z-Score of 1.85 (grey zone), revenue growth of +1.8% YoY.

Neutral

Analyst Consensus

Strong Buy

Wall Street consensus estimates — not a PMP forecast · Updated Aug 31, 2026

Analyst Recommendations38 analysts · 2026-08-01
9
22
7
Strong Buy 9Buy 22Hold 7Sell 0Strong Sell 0
ABBVIE INC. (ABBV) Valuation & P/E History →ABBVIE INC. (ABBV) Financial Statements →
Share:

Explore More Stocks

AAPLMSFTNVDAGOOGLAMZNMETATSLAJPMWMTVView all stocks →